MRES (Institute of Biomedical Research) Debt-to-Asset : 0.70 (As of Dec. 2010)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Institute of Biomedical Research Debt-to-Asset?

Institute of Biomedical Research MRES +7.41% Debt-to-Asset is 0.70 as of Dec. 2010.

Institute of Biomedical Research's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2010 was $0.46 Mil. Institute of Biomedical Research's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2010 was $0.00 Mil. Institute of Biomedical Research's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2010 was $0.66 Mil. Institute of Biomedical Research's debt to asset for the quarter that ended in Dec. 2010 was 0.70.

Institute of Biomedical Research  (OTCPK:MRES) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Institute of Biomedical Research Debt-to-Asset Related Terms

Institute of Biomedical Research Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Institute of Biomedical Research's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Institute of Biomedical Research Debt-to-Asset Chart

Institute of Biomedical Research Annual Data
Trend Dec03 Dec04 Mar06 Mar07 Mar08 Mar09 Mar10
Debt-to-Asset
Get a 7-Day Free Trial 1.27 0.00 0.00 1.87 5.29

Institute of Biomedical Research Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 5.29 2.29 2.37 0.70

MRES vs HSTC, NTRR, VITIF: Debt-to-Asset Comparison

For the Biotechnology subindustry, Institute of Biomedical Research's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Institute of Biomedical Research Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Institute of Biomedical Research's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Institute of Biomedical Research's Debt-to-Asset falls into.


Institute of Biomedical Research Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Institute of Biomedical Research's Debt-to-Asset for the fiscal year that ended in Mar. 2010 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.402 + 0) / 0.076
=5.29

Institute of Biomedical Research's Debt-to-Asset for the quarter that ended in Dec. 2010 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.461 + 0) / 0.655
=0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.70 mean?
Institute of Biomedical Research (MRES) has a Debt-to-Asset of 0.70 as of Dec. 2010. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Institute of Biomedical Research and its competitors.
Is Institute of Biomedical Research's Debt-to-Asset too high?
Institute of Biomedical Research's current Debt-to-Asset is 0.70.
How does Institute of Biomedical Research's Debt-to-Asset compare to HSTC and NTRR?
Institute of Biomedical Research's Debt-to-Asset of 0.70 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Institute of Biomedical Research and its competitors. Institute of Biomedical Research's current Debt-to-Asset is 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Institute of Biomedical Research stock overvalued right now?
Institute of Biomedical Research (MRES) has a current Debt-to-Asset of 0.70. The current Debt-to-Asset is 0.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Institute of Biomedical Research (MRES), the current Debt-to-Asset is 0.70 as of Dec. 2010. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Institute of Biomedical Research Business Description

Address Dubai Science Park, 13th Floor, South Tower, Dubai, ARE, 416452
Institute of Biomedical Research Corp is a biomedical research and development company. The company is focused on alternative plant-based food and medicine and mental health therapeutic research. The company uses brand name M2Bio Sciences engaged in deploying artificial intelligence, science and medicine, clinical research, and emerging technologies.